Abstract:Background Hepatocyte carcinoma (HCC) is one of the most common malignancies worldwide. Despite many achievements in diagnosis and treatment, HCC mortality remains high due to the malignant nature of the disease. Novel approaches, especially for targeted therapy, are being extensively explored. Gene therapy is ideal for such purpose for its specific expression of exogenous genes in HCC cells driven by tissue-specific promoter. However strategies based on correction of mutations or altered expressions of genes responsible for the development/progression of HCC have limitations because these aberrant molecules are not presented in all cancerous cells. In the current work, we adopted a novel strategy by targeting the DNA replication step which is essential for proliferation of every cancer cell. Methods A recombinant adenovirus with alpha fetoprotein (AFP) promoter-controlled expressions of artificial microRNAs targeting DNA polymerases α, δ, ε and recombinant active Caspase 3, namely Ad/AFP-Casp-AFP-amiR, was constructed. Results The artificial microRNAs could efficiently inhibit the expression of the target polymerases in AFP-positive HCC cells at both RNA and protein levels, and HCC cells treated with the recombinant virus Ad/AFP-Casp-AFP-amiR exhibited significant G0/1 phase arrest. The proliferation of HCC cells were significantly inhibited by Ad/AFP-Casp-AFP-amiR with increased apoptosis. On the contrary, the recombinant adenovirus Ad/AFP-Casp-AFP-amiR did not inhibit the expression of DNA polymerases α, δ or ε in AFP-negative human normal liver cell HL7702, and showed no effect on the cell cycle progression, proliferation or apoptosis. Conclusions Inhibition of DNA polymerases α, δ and ε by AFP promoter-driven artificial microRNAs may lead to effective growth arrest of AFP-positive HCC cells, which may represent a novel strategy for gene therapy by targeting the genes that are essential for the growth/proliferation of cancer cells, avoiding the limitations set by any of the individually altered gene.

Advance in Role of Caspase-3 in the Gene Therapy of Hepatitis C

Treatment of Hepatitis C Virus Core-Positive Hepatocytes with the Transfer of Recombinant Caspase-3 Using the 2',5'-Oligoadenylate Synthetase Gene Promoter.

In vivo treatment of HCV core-positive HepG2 cells with the transfer of recombinant caspase-3 using a 2'-5' OAS promoter.

DNA Polymerases as targets for gene therapy of hepatocellular carcinoma

Antitumor Potential of SLPI Promoter Controlled Recombinant Caspase-3 Expression in Laryngeal Carcinoma

Construction of Recombinant Adenovirus Carrying Hepatitis C Virus Nonstructural Protein 3 Gene

Advance in Gene Therapy of Tumors

Progress of Gene Therapy in Hepatitis C by RNAi

The expression significance of caspase-3 in the tissne of liver cancer and the relationship with HBV infection

Inhibitory Effect of Recombinant Adenovirus Carrying Immunocaspase-3 on Hepatocellular Carcinoma

Effect of Hepatitis c Virus NS3 Gene on Biological Charictarization of Human Hepatocyte

Construction of Recombinant Caspase-3 Eukaryotic Expression Plasmid and Its Expression Mediated by Vector Pcdna3.1(+) in Pancreatic Carcinoma Cells

[Research Advances on Treatment of Hepatitis C Infection Based on RNA Interference and Microrna Modulation].

Cloning and identification of human gene 2 transactivated by nonstructural protein 3 of hepatitis C virus

Procaspase-3 Enhances in Vitro Effect of Cytosine Deaminase-Thymidine Kinase Fusion Disuicide Gene Therapy System on Human Ovarian Carcinoma

Gene Mutation of Stop Coden in 3' Untranslated Region of Hepatitis C Virus

The Effect of Hepatitis C Virus NS3 Gene on the Expression of Phosphorylate Tyrosine Protein in Human Hepatocyte

Caspase-3 and Apotosis of Human Hepatoma Cell

[Current Status, Treatment and Prospect of Patients with Chronic Hepatitis C Genotype 3 in China].

Advances in small interfering RNA therapy for hepatitis C

Recent Advance in Antiviral Drugs for Hepatitis C.